


CLAIMS

1. A compound of formula (Ia) or (Ib)



or a pharmaceutically acceptable salt thereof,

5 wherein:

A is a 3-14 membered heterocycle substituted with R^A;

B is C₆-C₁₄-aryl or 5-14 membered heteroaryl substituted with R¹, R² and R³;

L is selected from a covalent bond, -C≡C-, -CHR^L-, -CH₂CHR^L-, -O-, -OCH₂-, and -CH₂O-; and

10 R¹, R², and R³ are independently selected from hydrogen, halogen, cyano, C₁-C₆-alkylsulfonyl, R^bR^cN, C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkyl, halo-C₁-C₆-alkoxy, hydroxy-C₁-C₆-alkyl, C₆-C₁₄-aryl, C₃-C₁₀-cycloalkyl, 3-14 membered heterocyclyl, 5-14 membered heteroaryl, C₆-C₁₄-aryloxy, C₃-C₁₀-cycloalkyloxy, 3-14 membered heterocyclyloxy, and 5-14 membered heteroaryloxy, wherein said C₃-C₁₀-cycloalkyl, C₆-C₁₄-aryl, 3-14 membered heterocyclyl, 5-14 membered heteroaryl, C₆-C₁₄-aryloxy, C₃-C₁₀-cycloalkyloxy, 3-14 membered heterocyclyloxy, and 5-14 membered heteroaryloxy are optionally substituted with one or more substituents that are independently selected from halogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and carbamoyl;

20 R^A is selected from hydrogen and C₁-C₆-alkyl;

R^b and R^c are independently selected from hydrogen, C₁-C₆-alkyl and C₆-C₁₄-aryl; and

25 R^L is selected from hydrogen, C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, alkoxy-C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₆-C₁₄-aryl, and halo-C₆-C₁₄-aryl.

2. The compound of formula (Ia) or (Ib) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (Ia) or (Ib) is not selected from:

(4aS,8aS)-6-[4-[[4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

30

- 68 -

(4aR,8aR)-6-[4-[[4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; and
rac-(4aS,8aS)-6-[4-(2-methylallyl)piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (CAS 1941372-36-6).

- 5 3. The compound of formula (Ia) or (Ib) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein A is azetidine or 7-azaspiro[3.5]nonan-7-yl and R^A is hydrogen.
4. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein B is phenyl substituted with R¹, R²
10 and R³.
5. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein:
L is selected from a covalent bond, -CHR^L-, -CH₂CH₂-, -O-, -OCH₂-, and -CH₂O-; and
15 R^L is hydrogen or halo-C₆-C₁₄-aryl.
6. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein L is selected from a covalent bond, -O-, -CH₂-, -CH₂CH₂-, and -CH₂O-.
7. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 4, or a
20 pharmaceutically acceptable salt thereof, wherein L is a covalent bond or -O-.
8. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from halogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, halo-C₁-C₆-alkoxy, hydroxy-C₁-C₆-alkyl, C₆-C₁₄-aryloxy, C₆-C₁₄-aryl, and C₃-C₁₀-cycloalkyl, wherein said C₃-C₁₀-cycloalkyl, C₆-C₁₄-aryloxy
25 and C₆-C₁₄-aryl are substituted with 1-2 substituents that are independently selected from halogen and halo-C₁-C₆-alkyl.
9. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from C₆-C₁₄-aryloxy, halo-C₁-C₆-alkyl and C₃-C₁₀-cycloalkyl substituted with halo-C₁-C₆-alkyl.

- 69 -

10. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from phenoxy, CF_3 and (trifluoromethyl)cyclopropyl.
11. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R^2 is selected from hydrogen and halogen.
12. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen or fluoro.
13. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydrogen.
14. The compound of formula (Ia) or (Ib) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein:
- A is a 3-14 membered heterocycle;
- B is C_6 - C_{14} -aryl substituted with R^1 and R^2 ;
- L is selected from a covalent bond, $-CH_2CH_2-$, $-CHR^L-$, $-O-$ and $-CH_2O-$;
- R^L is hydrogen or halo- C_6 - C_{14} -aryl;
- R^1 is selected from halogen, C_1 - C_6 -alkyl, halo- C_1 - C_6 -alkyl, halo- C_1 - C_6 -alkoxy, hydroxy- C_1 - C_6 -alkyl, C_6 - C_{14} -aryloxy, C_6 - C_{14} -aryl, and C_3 - C_{10} -cycloalkyl, wherein said C_3 - C_{10} -cycloalkyl, C_6 - C_{14} -aryloxy and C_6 - C_{14} -aryl are substituted with 1-2 substituents that are independently selected from halogen and halo- C_1 - C_6 -alkyl; and
- R^2 is selected from hydrogen and halogen.
15. The compound of formula (Ia) or (Ib) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
- A is a 3-14 membered heterocycle;
- B is C_6 - C_{14} -aryl substituted with R^1 and R^2 ;
- L is a covalent bond or $-O-$;
- R^1 is selected from C_6 - C_{14} -aryloxy, halo- C_1 - C_6 -alkyl and C_3 - C_{10} -cycloalkyl substituted with halo- C_1 - C_6 -alkyl; and
- R^2 is hydrogen or halogen.

- 70 -

16. The compound of formula (Ia) or (Ib) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

A is azetidine or 7-azaspiro[3.5]nonan-7-yl;

B is phenyl substituted with R¹ and R²;

5 L is selected from a covalent bond, -CH₂- or -O-;


R¹ is selected from phenoxy, CF₃ and (trifluoromethyl)cyclopropyl; and

R² is hydrogen or fluoro.

17. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, selected from the compounds disclosed in
10 Table 1.


18. The compound of formula (Ia) or (Ib) according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, selected from:

(4aR,8aR)-6-[3-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]azetidine-1-carbonyl]-
4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one



15

(4aS,8aS)-6-(3-(4-phenoxyphenyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-
b][1,4]oxazin-3(4H)-one




; and


(-)- or (+)-trans-6-[2-[2-Fluoro-4-(trifluoromethyl)phenoxy]-7-azaspiro[3.5]nonane-
7-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

20


- 71 -



19. A process of manufacturing the compounds of formula (Ia) or (Ib) according to any one of claims 1 to 18, or pharmaceutically acceptable salts thereof, comprising:
 reacting a first amine 4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one
 (1)



with a second amine of formula **2**, wherein A, L, and B are as defined in any one of claims 1 to 18



- in the presence of a base and a urea forming reagent,
 to form said compound of formula (Ia) or (Ib).
20. A compound of formula (Ia) or (Ib) according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, when manufactured according to the process of claim 19.
21. A compound of formula (Ia) or (Ib) according to any one of claims 1 to 18 and 20, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.
22. A pharmaceutical composition comprising a compound of formula (Ia) or (Ib) according to any one of claims 1 to 18 and 20, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.

- 72 -

23. The use of a compound of formula (I) according to any one of claims 1 to 18 and 20,
or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition
according to claim 22 for the treatment or prophylaxis of neuroinflammation,
neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory
5 bowel disease in a mammal.
24. The use of a compound of formula (I) according to any one of claims 1 to 18 and 20,
or a pharmaceutically acceptable salt thereof, or of a pharmaceutical composition
according to claim 22 for the treatment or prophylaxis of multiple sclerosis,
Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic
10 brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression,
hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain,
chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated
with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome
and/or visceral pain in a mammal.
- 15 25. A compound of formula (I) according to any one of claims 1 to 18 and 20, or a
pharmaceutically acceptable salt thereof, or of a pharmaceutical composition
according to claim 22 for use in the treatment or prophylaxis of neuroinflammation,
neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory
bowel disease in a mammal.
- 20 26. A compound of formula (I) according to any one of claims 1 to 18 and 20, or a
pharmaceutically acceptable salt thereof, or of a pharmaceutical composition
according to claim 22 for use in the treatment or prophylaxis of multiple sclerosis,
Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic
brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression,
25 hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain,
chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated
with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome
and/or visceral pain in a mammal.
27. The use of a compound of formula (I) according to any one of claims 1 to 18 and 20,
30 or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for
the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases,
pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.

- 73 -

28. The use of a compound of formula (I) according to any one of claims 1 to 18 and 20,
or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for
the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's
disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke,
5 epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon
carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy,
acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal
pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
29. A method for the treatment or prophylaxis of neuroinflammation, neurodegenerative
10 diseases, pain, cancer, mental disorders, and/or inflammatory bowel disease in a
mammal, which method comprises administering an effective amount of a
compound of formula (I) according to any one of claims 1 to 18 and 20, or a
pharmaceutically acceptable salt thereof, or of a pharmaceutical composition
according to claim 22 to the mammal.
- 15 30. A method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease,
Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury,
neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular
carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy
induced neuropathy, acute pain, chronic pain, spasticity associated with pain in a
20 mammal, abdominal pain, abdominal pain associated with irritable bowel syndrome
and/or visceral pain which method comprises administering an effective amount of a
compound of formula (I) according to any one of claims 1 to 18 and 20, or a
pharmaceutically acceptable salt thereof, or of a pharmaceutical composition
according to claim 22 to the mammal.
- 25 31. The invention as described hereinbefore.